stoxline Quote Chart Rank Option Currency Glossary
Matinas BioPharma Holdings, Inc. (MTNB)
0.16  0.005 (3.23%)    06-13 15:59
Open: 0.159
High: 0.16
Volume: 552,049
Pre. Close: 0.155
Low: 0.1547
Market Cap: 40(M)
Technical analysis
2024-06-13 4:45:00 PM
Short term     
Mid term     
Targets 6-month :  0.2 1-year :  0.21
Resists First :  0.17 Second :  0.18
Pivot price 0.16
Supports First :  0.14 Second :  0.12
MAs MA(5) :  0.15 MA(20) :  0.16
MA(100) :  0.21 MA(250) :  0.23
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  43.1 D(3) :  37.2
RSI RSI(14): 41.6
52-week High :  0.88 Low :  0.1
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ MTNB ] has closed above bottom band by 44.8%. Bollinger Bands are 78.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.16 - 0.16 0.16 - 0.16
Low: 0.15 - 0.15 0.15 - 0.15
Close: 0.16 - 0.16 0.16 - 0.16
Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Headline News

Fri, 07 Jun 2024
Matinas BioPharma (MTNB) in Focus: Stock Moves 6% Higher - Yahoo Movies UK

Fri, 10 May 2024
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q1 2024 Earnings Call Transcript - Yahoo Finance

Tue, 07 May 2024
Matinas BioPharma's LNC Platform for the Delivery of Small - GlobeNewswire

Wed, 03 Apr 2024
Matinas BioPharma Prices $10 Million Registered Direct Offering - GlobeNewswire

Mon, 01 Apr 2024
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript - Yahoo Finance

Thu, 28 Mar 2024
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 217 (M)
Held by Insiders 2.1048e+008 (%)
Held by Institutions 2.9 (%)
Shares Short 4,580 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -2.297e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 81.9 %
Return on Equity (ttm) -37.8 %
Qtrly Rev. Growth 2.16e+006 %
Gross Profit (p.s.) 0
Sales Per Share -37.22
EBITDA (p.s.) -7.29189e+006
Qtrly Earnings Growth -0.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 2.69
Stock Dividends
Dividend 0
Forward Dividend 3.49e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android